VERA

Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.

Wall Street analysts forecast VERA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERA is 68.22 USD with a low forecast of 45.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Vera Therapeutics Inc revenue for the last quarter amounts to -83.93M USD, increased 68.53 % YoY.

Vera Therapeutics Inc. EPS for the last quarter amounts to -62039000.00 USD, increased 67.12 % YoY.

Vera Therapeutics Inc (VERA) has 112 emplpoyees as of December 15 2025.

Today VERA has the market capitalization of 3.49B USD.